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Summary
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy associated with Notch 
pathway mutations. While both normal activated and leukemic T cells can utilize aerobic 
glycolysis to support proliferation, it is unclear to what extent these cell populations are 
metabolically similar and if differences reveal T-ALL vulnerabilities. Here we show that aerobic 
glycolysis is surprisingly less active in T-ALL cells than proliferating normal T cells and T-ALL 
cells are metabolically distinct. Oncogenic Notch promoted glycolysis but also induced metabolic 
Address correspondence to: jeff.rathmell@vanderbilt.edu. 
Author Contributions
J.C.R and R.J.K. designed the study and wrote the manuscript; R.J.K., C.E.B., A.G.N., S.C., V.A.G., A.N.M., P.G.H., P.J.S. and 
M.O.W. performed the experiments; K.L.R. and A.E.J.Y. provided human T-ALL samples; and P.J.S., A.A.C., W.K.R., T.L., M.O.W., 
E.D.A., T.R.G., J.W.L. gave technical support and conceptual advice.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Cell Metab. Author manuscript; available in PMC 2017 April 12.
Published in final edited form as:
Cell Metab. 2016 April 12; 23(4): 649–662. doi:10.1016/j.cmet.2016.03.008.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
stress that activated 5′ AMP activated kinase (AMPK). Unlike stimulated T cells, AMPK actively 
restrained aerobic glycolysis in T-ALL cells through inhibition of mTORC1 while promoting 
oxidative metabolism and mitochondrial Complex I activity. Importantly, AMPK-deficiency or 
inhibition of Complex I led to T-ALL cell death and reduced disease burden. Thus AMPK 
simultaneously inhibits anabolic growth signaling and is essential to promote mitochondrial 
pathways that mitigate metabolic stress and apoptosis in T-ALL.
Graphical Abstract
Introduction
While resting cells typically rely on mitochondrial oxidative phosphorylation to meet bio-
energetic needs, cancer cells often utilize a metabolic program known as aerobic glycolysis 
(Cantor and Sabatini, 2012; Hanahan and Weinberg, 2011). Aerobic glycolysis is 
characterized by increased glucose import and flux through glycolysis and subsequent 
production of lactate even under normoxic conditions (Warburg et al., 1927). Tumor cells are 
thought to utilize aerobic glycolysis to allow diversion of glycolytic intermediates to 
biosynthetic pathways to generate lipids, nucleotides, and amino acids necessary for cell 
growth and division (Vander Heiden et al., 2009).
T cell acute lymphoblastic leukemia (T-ALL) is a rapidly proliferating malignancy that, 
while generally well treated (Pui et al., 2008), has a poor prognosis upon relapse or with 
advanced age at onset (Bhojwani and Pui, 2013; Oudot et al., 2008). T-ALL is frequently 
associated with Notch signaling pathway mutations and greater than 60% of human patients 
exhibit activating mutations in the Notch pathway (Weng et al., 2004). Although Notch can 
promote glycolytic metabolism in T-ALL cell lines (Palomero et al., 2007) and developing T 
cells (Ciofani and Zuniga-Pflucker, 2005), recent work has suggested that Notch signaling 
also drives mitochondrial oxidative metabolism in the context of macrophage polarization 
(Xu et al., 2015) and in T-ALL cell lines (Palomero et al., 2006). Oncogenic Notch can 
promote PI3K pathway (Palomero et al., 2007) and c-Myc signaling (Palmer et al., 2015; 
Palomero et al., 2006) that promotes glutamine oxidation (Herranz et al., 2015). Stimulated 
Kishton et al. Page 2
Cell Metab. Author manuscript; available in PMC 2017 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
normal T cells also activate the PI3K and c-Myc pathways and utilize aerobic glycolysis to 
rapidly proliferate and carry out immunological functions (Gerriets et al., 2015; Macintyre et 
al., 2014; Wang et al., 2011). It is unclear, however, to what extent metabolic programs of 
activated or transformed T cells were similar and if differences may reveal T-ALL 
vulnerabilities.
In contrast to PI3K, 5′ AMP-activated kinase (AMPK) can inhibit mTORC1 signaling 
(Gwinn et al., 2008; Inoki et al., 2003). AMPK is activated by the tumor suppressor 
LKB1(Shaw et al., 2004) and can have growth suppressive functions in cancer settings 
(Faubert et al., 2013). Further, pharmacological activation of AMPK can slow the growth of 
some tumors (Hirsch et al., 2009) and AMPK may act to inhibit tumor growth in T-ALL 
(Mavrakis et al., 2010). Conversely, multiple oncogenic signals, including oncogenic Ras 
and Myc, can generate metabolic stress (Liu et al., 2012; Moiseeva et al., 2009), and AMPK 
may promote cancer cell survival under such conditions. Indeed, LKB1 loss sensitizes to 
metabolic stress(Shackelford et al., 2013) and AMPK may be important to mitigate 
metabolic stress in myeloid leukemia initiating cells(Saito et al., 2015) and activated T cells 
in vivo (Blagih et al., 2015).
Here we compared the metabolic programs of primary T-ALL and normal proliferative T 
cells. As anticipated, primary human T-ALL samples used and required aerobic glycolysis. 
However, T-ALL glucose metabolism was surprisingly restrained compared to the glycolytic 
metabolism of normal proliferating T cells and T-ALL and proliferating T cells had different 
global metabolomes. Consistent with chronic metabolic stress, AMPK was activated and 
suppressed mTORC1 signaling and glycolysis while supporting mitochondrial metabolism 
that we found essential for T-ALL cell survival in vivo. Thus, T-ALL cells utilize a distinct 
metabolic program in which Notch-induced metabolic stress leads to AMPK activation that 
plays dual roles to inhibit anabolic metabolism while also promoting T-ALL cell survival 
through positive regulation of mitochondrial metabolism.
Results
Primary T-ALL cells exhibit increased glycolysis that is necessary for cell survival and 
disease progression
The metabolic profile of primary T-ALL cells is poorly understood. Therefore, we examined 
the expression levels of the glycolytic proteins Glut1, the primary glucose transporter in T 
cells (Macintyre et al., 2014), and Hexokinase 2 (HK2), a hexokinase isoform commonly 
associated with aerobic glycolysis (Gershon et al., 2013; Wolf et al., 2011), in primary 
human patient peripheral blood samples of T-ALL. Both Glut1 (Figure 1A, S1A) and HK2 
(Figure 1B, S1B) were significantly elevated in T-ALL cells compared to naïve T cells from 
healthy human blood donors. Interestingly, the expression of HK1 (Figure 1C, S1C) was 
significantly lower in T-ALL cells than in naïve T cells. Human T-ALL cell lines also 
showed a similar pattern of expression of Glut1, HK1, and HK2 (Figure 1D).
We next sought to determine if T-ALL cells used aerobic glycolysis relative to normal 
resting T cell counterparts. Relative to resting T cells primary human TALL cells had 
increased rates of glucose uptake (Figure 1E). We then compared the metabolic activity of 
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primary T-ALL cells with resting T cells using a well-characterized primary murine model 
of Notch driven T-ALL in which retroviral expression of oncogenic intracellular Notch 
(ICN1) in hematopoietic progenitor cells (HPCs) drives T-ALL initiation and maintenance 
(Chiang et al., 2008). Primary murine Notch driven T-ALL exhibited increased oxygen 
consumption rate (OCR) and lactate production as measured by extracellular acidification 
rate (ECAR) using extracellular flux analysis (Figure 1F) compared to naïve murine T cells. 
Primary human T-ALL also exhibited increased ECAR relative to naïve human T cells 
(Figure S1D).
Although T-ALL cells utilized aerobic glycolysis, the dependence of these cells on this 
metabolic program was unclear. Therefore, we treated primary human T-ALL samples with 
2-deoxyglucose (2DG) to inhibit glycolysis. Because each sample was comprised of a mixed 
population of tumor cells (CD4+CD8+) and non-malignant T cells (CD4+ or CD8+), the 
effects of 2DG on transformed and non-malignant T cells were compared within the same 
sample. While the percentage of cancer cells in the total live cell population declined over 
time with 2DG treatment, the fraction of non-malignant CD4+ T cells remained unchanged 
or increased (individual patient samples shown in Figures 1G, S1E, S1F). Isolated resting 
CD4+ T cells from healthy independent donors also did not show reduced viability upon 
2DG treatment (Figure S1G).
To directly test the dependence of T-ALL cells on aerobic glycolysis in vivo, Glut1 was 
conditionally deleted in T-ALL. We generated T-ALL from a Glut1 floxed, inducible Cre 
background (Glut1fl/fl; Rosa26CreERT2) in which Cre is activated by treatment with 
tamoxifen to delete Glut1. Primary T-ALL cells were transplanted into secondary recipient 
mice, which were treated with tamoxifen or vehicle and monitored for survival. Tamoxifen-
treated mice survived significantly longer than vehicle-treated mice (Figure 1H), supporting 
a dependence of T-ALL cells on Glut1. We also examined T-ALL cells with acute deletion 
of Glut1. In these studies secondary recipients of Glut1fl/fl;Rosa26CreERT2 background 
primary T-ALL were treated with tamoxifen starting 10 days after transplant, then analyzed 
after an additional 5 days. This protocol showed a significant reduction in Glut1 expression 
and the number of T-ALL cells in the spleens of treated mice (Figure 1I and S2A).
To further support a role for glucose metabolism, HK2 was conditionally deleted in T-ALL 
cells (Figure S2B). This increased animal survival (Figure S2C) and reduced T-ALL burden 
(Figure S2D). HK2 can promote generation of nucleotides through the pentose phosphate 
pathway (PPP) (Patra et al., 2013). T-ALL cells isolated five days after HK2 deletion had 
decreased PPP flux (Figure S2E) and reduced nucleotide and nucleoside levels (Figure S2F, 
Supplemental Table 1). We also observed an increase in non-phosphorylated glucose and a 
reduction in fructose 1,6-bisphosphate consistent with reduced glycolytic flux (Figure S2G). 
Importantly, Cre activation itself had no effect on mouse survival (Figure S3A), tumor 
burden (Figure S3B–S3E), or PPP flux (Figure S3F).
Glycolysis is selectively restrained in T-ALL
As T-ALL cells exhibited increased glycolytic activity relative to naïve T cells and required 
this pathway, we sought to compare T-ALL metabolism to that of normally proliferating T 
cells. Primary TALL was compared to naïve ex vivo murine T cells and T cells that were 
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stimulated for 24 or 48 hours with plate bound anti-CD3 and anti-CD28 using non-targeted 
mass spectrometry metabolomics analysis. Clustering and principle component analysis 
(PCA) showed that the metabolomic profile of T-ALL cells is distinct from that of naïve ex 
vivo T cells as well as 24 and 48 hr activated T cells (Figure 2A, 2B, Supplemental Table 2). 
Pathway analysis of metabolomics data showed that T-ALL cells had increased 
concentrations of metabolites associated with the TCA cycle, glutathione metabolism, 
nucleotide synthesis and fatty acid oxidation when compared to naïve T cells (Supplemental 
Table 3). Compared to 48 hr stimulated T cells, T-ALL cells instead had increased 
concentrations of metabolites associated with the oxidation of amino and fatty acids and 
lower levels of metabolites associated with glycolytic metabolism, amino acid metabolism, 
nucleotide production, and mitochondrial activity (Supplemental Table 4). In direct 
metabolic measurements primary murine T-ALL cells were found to have consistent 
elevation of glucose uptake (Figure 2C), glycolytic flux through enolase (Figure 2D) and 
PPP flux (Figure 2E) compared to naïve T cells. However, these pathways were significantly 
lower in T-ALL than activated proliferating T cells. T-ALL cell mitochondrial content and 
membrane potential were, in contrast, similar to 48 hr stimulated T cells (Figure 2F, Figure 
S4A).
Oncogenic Notch regulates glycolytic and oxidative metabolism
Notch likely has diverse effects on metabolism. To examine oncogenic Notch signaling in T-
ALL metabolism, oncogenic Notch (ICN) was retrovirally transduced into primary murine 
hematopoietic progenitor cells (HPCs), the cell of origin of Notch-driven T-ALL (Chiang et 
al., 2008). ICN transduced cells were cultured for 4 days on OP9 stromal cells and compared 
to vector control infected cells. Notch-ICN resulted in increased cell size as measured by 
FSC in primary HPCs (Figure 3A). Conversely, gamma secretase inhibitor (GSI) inhibition 
of Notch signaling in Notch-dependent human T-ALL cell lines DND41 and HPB-ALL 
resulted in decreased FSC (Figure 3B). Notch-ICN also increased cell surface localized 
Glut1 in primary HPCs as measured in cells expressing Glut1myc (Figure 3C) and showed 
elevated total Glut1 and HK2 expression (Figure 3D). Conversely, GSI treatment of DND41 
and HPB-ALL cells decreased expression of HK2 (Figure 3E). Finally, retroviral expression 
of Notch-ICN resulted in increased glucose uptake in HPCs (Figure 3F).
Oncogenic Notch signaling also modulated mitochondrial metabolism. Notch-ICN 
transduced HPCs had increased expression of cytochrome C (Figure 3G), while GSI 
treatment of human T-ALL cell lines resulted in reduced cytochrome C (Figure 3H). Viral 
transduction of Notch-ICN into primary HPC cells also resulted in increased basal and 
maximal OCR (Figure 3I, 3J), mitochondrial content (Figure 3K, S5A) and membrane 
potential (Figure 3L, S5B). Reactive oxygen species (ROS) content as measured by DCFDA 
staining was not significantly altered (Figure S5C).
Notch signaling can activate both the PI3K/AKT/mTOR and c-Myc signaling pathways. To 
examine how oncogenic Notch signaling regulates metabolism in T-ALL, we treated Notch 
transduced HPCs with the PI3K pathway inhibitors rapamycin, LY294002 and PP242, and 
the bromodomain inhibitor JQ1, previously shown to inhibit c-myc activity (Delmore et al., 
2011), and measured effects on metabolism. Each treatment resulted in a significant 
Kishton et al. Page 5
Cell Metab. Author manuscript; available in PMC 2017 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
reduction in cell size (Figure S5D), surface Glut1 (Figure S5E) and HK2 expression (Figure 
S5F).
Oncogenic Notch signaling in T-ALL results in metabolic stress and AMPK pathway 
activation
Because the PI3K pathway mediated metabolic changes in Notch-ICN transduced cells, we 
examined this pathway in T cells and T-ALL. In HPCs, Notch-ICN increased phospho-
mTOR, yet the mTORC1 downstream effector phospho-S6 ribosomal protein remained 
surprisingly low (Figure S5G). Similarly, primary murine T-ALL cells displayed increased 
phospho-mTOR compared to naïve and 48 hr in vitro stimulated T cells, but levels of 
phospho-S6 and -4EBP1 in T-ALL cells were far below that of stimulated T cells and pS6K 
levels were reduced relative to total S6K (Figure 4A).
These data suggested AMPK signaling pathway may be activated in TALL to suppress 
mTORC1 activity and oncogenic signals may generate metabolic stresses that activate the 
AMPK pathway (Liu et al., 2012). Compared to naïve T cells, phosphorylation of AMPK 
and the AMPK target, ACC, were indeed increased in both primary murine T-ALL and 
activated T cells (Figure 4A). However, T-ALL cells showed phosphorylation of RAPTOR 
at Ser792 (Figure 4A), while activated T cells did not. Phosphorylation of this site by AMPK 
can negatively regulate glycolysis and mTORC1 (Gwinn et al 2008). Naïve T cells also 
exhibited high levels of phospho-RAPTOR S792 that correlate with low glycolysis and 
mTORC1 activity. Phospho-ACC was also elevated in two independent primary human T-
ALL (Figure 4B) and Notch-ICN was sufficient to activate AMPK in primary HPCs (Figure 
4C). Conversely, inhibition of Notch in human T-ALL cell lines decreased AMPK pathway 
activity (Figure 4D). Because AMPK is regulated in part by ATP, ADP, and AMP, ATP 
levels were assessed in T-ALL compared to naïve ex vivo T cells. Primary murine T-ALL 
cells had reduced levels of ATP compared to naïve T cells (Figure 4E), as well as decreased 
ratios of ATP/AMP (Figure 4F) and ATP/ADP (Figure 4G), suggesting that T-ALL cells 
experience chronic ATP-insufficiency that may promote AMPK pathway activation.
AMPK signaling suppresses mTORC1 activity in primary T-ALL, resulting in decreased 
aerobic glycolysis
As T cells exclusively express the catalytic α1 subunit of AMPK (MacIver et al., 2011), T-
ALL was generated on an AMPKα1fl/fl;Rosa26CreERT2 background to directly test the role 
of AMPK in TALL physiology and survival. Primary T-ALL was transplanted into cohorts 
of sublethally irradiated recipients that were treated with tamoxifen for 4 days after 10 days 
engraftment. Consistent with the AMPKα1 isoform as the major AMPKα subunit in T-ALL, 
tamoxifen treatment resulted in a marked decrease in total AMPKα protein expression 
levels, along with a reduction in the phosphorylation of AMPK target ACC (Figure 5A). The 
loss of AMPK in T-ALL also resulted in a reduction of inhibitory phosphorylation of 
RAPTOR (Figure 5A) and increased mTORC1 activity, with higher levels of phospho-S6 
kinase, phospho-S6 ribosomal protein, and phospho-4EBP1 (Figure 5A). Glut1 and HK2 
were also increased in AMPKα1 deficient T-ALL cells (Figure 5B) and AMPK deletion in 
vivo led to an increase in ECAR (Figure 5C), and an increase in the expression of genes in 
the PPP (Figure 5D, Supplemental Table 5). Importantly, alterations in glycolytic flux were 
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not due to Cre activation (Figure S3G). Metabolomic analysis revealed increased levels of 
metabolites (Figure 5E–G, Supplemental Table 6) associated with mTORC1-regulated 
anabolic synthesis of nucleotides (Ben-Sahra et al., 2013; Robitaille et al., 2013). AMPK, 
therefore, actively restrains mTORC1 signaling and de novo nucleotide synthesis of T-ALL 
cells in vivo.
AMPK pathway signaling promotes oxidative metabolism through regulation of 
mitochondrial Complex I
AMPK can promote mitochondrial metabolism to mitigate metabolic stress (Lantier et al., 
2014). Consistent with this role, we observed a reduction in the OCR (Figure 6A) and ratio 
of OCR/ECAR was significantly lowered in AMPKα1 deficient T-ALL cells (Figure 6B), 
indicating that the loss of AMPK resulted in a shift towards increased glycolysis. No 
decrease was observed in OCR as a result of Cre activation alone (Figure S3H). OCR 
coupled to ATP production, defined by oligomycin-sensitive OCR, was also significantly 
reduced in AMPKα1 deficient T-ALL cells (Figure 6C). Further, metabolomics analysis 
showed an increase in the ratio of NAD+/NADH in AMPKα1 deficient T-ALL cells (Figure 
6D) and we observed an increase in ROS levels (Figure 6E), suggesting AMPK was 
essential to maintain a sufficient reductive mitochondrial capacity. Analysis of mitochondrial 
gene expression revealed that AMPK selectively regulated the expression of electron 
transport Complex I (Figure 6F, S6A, Supplemental Table 7), although we observed only 
modest reduction of NDUFS1 protein, a component of Complex I, in AMPKα1 deficient T-
ALL cells (Figure S6B). Importantly, direct measurement of Complex I function revealed 
reduced activity in AMPKα1 deficient T-ALL cells (Figure 6G, S6C).
Loss of AMPK signaling or direct pharmacological inhibition of Complex I results in 
reduced T-ALL cell survival and slowed disease progression
We next tested the effects of AMPK deficiency in T-ALL on disease progression. Despite 
increased mTORC1 activity, acute deletion of AMPKα1 resulted in reduced numbers and 
percentages of splenic, lymph node, and bone marrow T-ALL cells (Figure 7A–C). 
Reductions were associated with increased T-ALL cell staining for Annexin V that indicate 
early apoptosis and reduced percentages of viable cells (Figure 7D). Cell proliferation, as 
measured by Ki67 staining, was not significantly altered (Figure S7A). T-ALL cell number 
and percentage were also decreased in the bone marrow following AMPKα1 deletion at a 
later time post tamoxifen treatment (Figure S7B), with similar increases in cell death (Figure 
S7C). Importantly, lower T-ALL numbers correlated with increased animal survival (Figure 
7E). Consistent with this role for AMPK to support T-ALL, analysis of two published data 
sets (Homminga et al., 2011; Sanghvi et al., 2014) indicated no loss of expression of 
AMPKα1 in human T-ALL compared with control cells (Figure S7D). Therefore, despite 
actively suppressing T-ALL anabolic metabolism, AMPK is essential for T-ALL cell 
survival and disease progression.
Because AMPK regulated mitochondrial Complex I, the effects of direct pharmacological 
inhibition of mitochondrial electron transport on T-ALL were tested. Primary murine T-ALL 
cells were treated along with naïve ex vivo T cells and 48 hr stimulated T cells with low 
doses of the Complex I inhibitor rotenone (100 nM, Figure 7F). Interestingly, while the 
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viability of both naïve and in vitro stimulated T cells was not significantly altered by low 
dose rotenone treatment, primary T-ALL cells were rapidly killed. Similar to rotenone, the 
clinically relevant Complex I inhibitor phenformin rapidly killed primary T-ALL cells while 
sparing both naïve and in vitro stimulated T cells (Figure 7G). Phenformin also led to a 
reduction in the mitochondrial oxygen consumption rate (Figure 7H), coupled with an 
increase in ECAR (Figure 7I) resulting in a reduction in the OCR/ECAR ratio (Figure S7E).
We next tested the pharmacological impact of phenformin on T-ALL in vivo. Wild type 
primary T-ALL was transplanted into cohorts of secondary recipient mice and dosed daily 
with phenformin or vehicle for 10 consecutive days. Mice were rested for 2 days then 
sacrificed for analysis. T-ALL cells from phenformin treated mice had elevated levels of 
cytoplasmic ROS (Figure 7J), consistent with Complex I inhibition (Li et al., 2003). 
Importantly, phenformin treatment reduced the number (Figure 7K) and percentage (Figure 
7L) of T-ALL cells in the treated mice and resulted in a significant increase in overall animal 
survival (Figure S7F).
Discussion
The metabolism of cancer cells has been largely defined relative to resting mature tissues. 
Comparisons of proliferative normal and transformed cells from similar origins may, 
however, reveal cancer specific vulnerabilities or selective weaknesses. Here we examined 
the metabolism of T-ALL cells in comparison to resting and proliferative T cells and found 
that T-ALL cells utilize aerobic glycolysis, but are restrained from reaching the levels of 
activated T cells. Specifically, Notch induced metabolic stress that led to AMPK activation 
that both slowed glycolysis and promoted mitochondrial oxidative metabolism to mitigate 
stress. Exacerbating this stress by AMPK or mitochondrial inhibition may provide a new 
approach to treat T-ALL.
Antigen stimulated effector T cells utilize aerobic glycolysis during rapid cellular 
proliferation to mount immune responses. Previous work has shown that, like many cancers 
(Liu et al., 2014a), inhibition of T cell glycolysis can result in reduced cell viability and loss 
of immunological function (Gerriets et al., 2015; Macintyre et al., 2014). Because of this, 
activated T cells have been proposed as a model for cancer metabolism (Macintyre and 
Rathmell, 2013). Activated T cells, however, have a short lifespan unless able to transition 
from glycolysis back to oxidative metabolism (Sukumar et al., 2013; van der Windt et al., 
2012). While cancer may select for maximal proliferation, cells with prolonged capacity for 
replication and survival are also favored. T-ALL cells thus appear reminiscent of long-lived 
T cells that have adapted to balance glycolysis with mitochondrial oxidative capacity.
Several factors may mediate this difference between activated T cells and T-ALL cells. First, 
our comparison is between acutely activated T cells and chronic oncogenic signals that drive 
anabolic growth. Indeed mitochondria are hyperpolarized in T cells of Systemic Lupus 
Erythematosus patients, suggesting that chronic autoimmunity may lead to mitochondrial 
compensation (Gergely et al., 2002). Likewise, the immune modulatory protein PD-1 can 
restrain T cell glycolysis (Patsoukis et al., 2015) and lead to functional exhaustion 
(Zinselmeyer et al., 2013) in chronic infection or cancer. Mechanisms that reprogram 
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chronically stimulated T cells are unclear, but AMPK was recently shown to be required to 
allow some T cell mediated immunity (Blagih et al., 2015) and may act similarly in T-ALL. 
Second, unlike T cell activation that induces a coordinated signal to promote T cell 
proliferation and viability, T-ALL cells are driven by limited oncogenic signals that may lead 
to imbalanced metabolic alterations. Although Notch can increase mitochondrial 
metabolism, this imbalance may promote metabolic stress.
Our data show a dual role for AMPK in T-ALL. AMPK has previously been shown to 
suppress aerobic glycolysis and progression of B cell leukemia through the inhibition of 
HIF1α (Faubert et al., 2013). Recent work has also indicated AMPK was necessary to 
maintain AML tumor initiating cell viability under conditions of metabolic stress through 
promoting the expression of Glut1 (Saito et al., 2015). We show AMPK acts in T-ALL to 
negatively regulate aerobic glycolysis and Glut1 while also maintaining mitochondrial 
function to promote cell survival. These data suggest a context specific role for AMPK. Our 
findings are consistent with the previously observed role for AMPK in the T cell lineage, 
where it can inhibit glycolysis and mTORC1 signaling, yet promote T cell survival (MacIver 
et al., 2011) and function in vivo (Blagih et al., 2015). ARK5, a regulator of AMPK pathway 
signaling, was also shown to be critical to mitigating ATP stress and promote hepatocellular 
carcinoma (Liu et al., 2012). Our data demonstrate that AMPK itself plays a critical role in 
murine T-ALL survival. AMPK activation would protect from metabolic stress both by 
reducing energy demand through inhibition of mTORC1-regulated anabolic growth and by 
promoting energy generation through increased mitochondrial Complex I and catabolic 
metabolism. The loss of AMPK in T-ALL resulted in increased mTORC1 signaling and 
anabolic metabolism while also leading to an increase in apoptosis. Any protective effect of 
increased PPP activity, therefore, was insufficient to prevent death. It is interesting that while 
AMPK was active in both activated T and T-ALL cells, RAPTOR was phosphorylated only 
in T-ALL cells, suggesting additional regulation.
The paradoxical dual role for AMPK was likely due to AMPK-induced support of 
mitochondrial metabolism. Indeed, AMPK deletion led to increased NAD/NADH ratio and 
ROS, demonstrating a requirement for AMPK to maintain cellular reductive capacity. This is 
consistent with previous work showing that AMPK activity was necessary to maintain tumor 
cell redox balance (Jeon et al., 2012). AMPK deficiency also led to reduced mitochondrial 
oxidative metabolism that was characterized by altered mitochondrial Complex I. The 
effects of AMPK deletion on Complex I may potentially be indirect, such as through HIF1α 
(Faubert et al., 2013) which can negatively regulate mitochondrial metabolism (Tello et al., 
2011). AMPK may also regulate activity of Complex I. While loss of LKB1 and AMPK 
activation sensitized non-small cell lung cancer cells to mitochondrial inhibition 
(Shackelford et al., 2013), we found mitochondrial metabolism directly limiting in T-ALL. 
T-ALL appear under basal metabolic stress and inhibition of mitochondrial Complex I was 
sufficient to result in rapid T-ALL cell death in vitro and in vivo.
Cancer cells must successfully balance the metabolic demands of rapid cellular proliferation 
with energetic requirements to maintain viability. Thus, interventions that deliberately skew 
this balance towards pro-growth activities may instead exacerbate stress and result in a loss 
of tumor cell viability. Similarly, excessive oncogenic signaling may actually result in the 
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loss of tumor cell viability (Chen et al., 2015). Metabolic stress may be a key and potentially 
limiting feature of oncogenesis. While our findings here are limited to Notch-induced T-
ALL, Ras and Myc can also each drive metabolic stress in tumor cells (Liu et al., 2012; 
Moiseeva et al., 2009). Further, unrestrained usage of aerobic glycolysis itself may reduce 
cell life span. Indeed, mutations that result in increased lymphocyte glycolysis can result in 
immunosuppression due to an inability to generate long-lived memory cells (Angulo et al., 
2013; Lucas et al., 2014). Moderated aerobic glycolysis along with alternative metabolic 
pathways may therefore be required for tumor cells to maintain proliferative capacity and 
viability over the long term. Mitochondrial metabolism appears limiting and may thus offer 
new therapeutic targets in the treatment of T-ALL.
Experimental procedures
Human samples and cell lines
DND-41, HPB-ALL and ALL-SIL cell lines were obtained from DSMZ (Braunschweig, 
Germany). Human T-ALL samples were obtained from the Children’s Oncology Group 
Biobanking Facility (5 samples), the University of North Carolina Cancer Hospital Tissue 
Procurement Facility (1 sample), or the Singapore Leukemia Tissue Bank (2 samples). 
Patient samples were chosen sequentially based solely on a diagnosis of T-ALL and 
availability of tumor samples obtained from peripheral blood prior to treatment. Samples 
were collected according to an IRB-approved tissue collection protocol at each institution, 
and were de-identified prior to use.
Mice
Mice were obtained from Jackson Laboratory or have been previously described (Gershon et 
al., 2013; Macintyre et al., 2014; Michalek et al., 2011). Eight to twelve week old C57BL/6J 
mice were used throughout. All procedures were performed under protocols approved by the 
Duke University Medical Center Institutional Animal Care and Use Committee (IACUC).
T-ALL mouse model
T-ALL was generated in mice as previously described (Herranz et al., 2015), with minor 
modifications. In brief, lineage negative hematopoietic cells were isolated from murine bone 
marrow using Miltenyi Lineage Cell Depletion Kit (130-090-858). Isolated cells were 
cultured for 16 hrs in X-VIVO 15 media (Lonza 04-418Q) with 100 ng/mL murine stem cell 
factor (Peprotech 250-03), 10 ng/mL murine IL3 (Peprotech 213-13), 10 ng/mL human IL6 
(Peprotech 200-06) and 50 ng/mL FLT3-ligand (Peprotech 250-31L). Cells were then treated 
with freshly made MSCV-ICN1-IRES-GFP or MSCV-ICN1-IRES-NGFR or vector control 
virus along with 8 μg/mL polybrene on retronectin coated plates and centrifuged for 45 min 
at 1200 rpm. Cells were rested for 2 hr and plated with fresh media with cytokine 
supplements for 24 hrs. Spinfection protocol was repeated 24 hrs later. 48 hrs after final 
spinfection, 5 × 104 transduced cells (identified by GFP or NGFR) along with 2 × 105 bone 
marrow cells for hemogenic support were injected via tail vein into lethally irradiated (9.0 
Gy split into two fractionated doses 4 hrs apart) syngeneic mice. Secondary recipient mice 
were irradiated with 4.5 Gy and received 2 × 105 T-ALL cells via tail vein.
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Retroviral packaging
Retroviral constructs were packaged in Plat-E cells. Plat-E cells were maintained in DMEM 
supplemented with 10% FBS, with 1 μg/mL puromycin and 10 μg/mL blasticidin. To 
produce virus, Plat-E cells at 70% confluency in a 6 well dish were transfected with 
construct plasmid along with Lipofectamine 2000 Transfection Reagent (Life Technologies). 
Media supernatant was removed 24 hrs post transfection, and fresh virus was collected 72 
and 96 hrs post transfection.
Drug treatment of mice
Mice were dosed with tamoxifen (Sigma T5648) dissolved in corn oil at a dosage of 75 
mg/kg body weight for 4 consecutive days starting 4 days after T-ALL transplantation for 
survival curve experiments or 10 days after T-ALL transplantation for acute deletion 
experiments. Mice were dosed with phenformin hydrochloride (Sigma P7045) dissolved in 
PBS at a dosage of 100 mg/kg body weight.
Human T-ALL cell line culture
DND-41, HPB-ALL and ALL-SIL cells were cultured between 5 × 105 and 2 × 106 cells per 
mL media in RPMI 1640 media supplemented with 10% FBS, 2 mM glutamine, 10 mM 
HEPES and 55 μM β-mercaptoethanol.
T Cell Isolation, Stimulation, and Culture
Murine or human total or CD4 T cells were isolated by magnetic bead negative and cultured 
in RPMI 1640 media supplemented with 10% FBS, 2 mM glutamine, 10 mM HEPES and 55 
μM β-mercaptoethanol. T cells were stimulated on plates with 5 μg/mL anti-CD3ε and anti-
CD28 antibodies (Pharmingen) for 24 or 48 hrs as indicated. Naïve T cells were cultured 
with 10 ng/mL IL-7. Activated T cells were washed off of stimulation plates and cultured 
with 5 ng/mL IL-2 for assays.
Primary T-ALL cell culture
Murine or human T-ALL cells were cultured in RPMI 1640 media supplemented with 10% 
FBS, 2 mM glutamine, 10 mM HEPES and 55 μM β-mercaptoethanol. IL-2 (10 ng/mL) and 
IL-7 (10 ng/mL).
Metabolomics
Nontargeted metabolomic analyses were performed as described using LC Q Exactive Mass 
Spectrometer (LC-QE-MS) (Thermo Scientific) (Liu et al., 2014b). Metaboanalyst was used 
to range-scale data and provide PCA and KEGG pathway analysis of metabolites 
significantly changed (1.5-fold difference, P<0.05)(www.metaboanalyst.ca/).
PCR Arrays
RNA was isolated from cells using RNeasy Plus Mini kit (Qiagen) following the 
manufacturers’ instructions. 1 μg total RNA was subjected to single-strand cDNA synthesis 
using the RT2 first strand kit (Qiagen). The cDNA was used in the Glucose Metabolism and 
Mitochondrial Energy Metabolism RT2 Profiler PCR arrays according to the manufacturer’s 
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instructions and assayed on a CFX384 (Biorad). Data were analyzed using the RT2 Profiler 
program supplied by Qiagen and normalized to the geometric mean of the housekeeping 
genes beta-actin, beta-glucuronidase and heat shock protein 90kDa alpha.
Immunoblotting
Immunoblotting was performed as described previously (Jacobs et al., 2008). Primary 
antibodies were followed by mouse- or rabbit-conjugated horseradish peroxidase (HRP). 
HRP-conjugated antibodies (anti-mouse or anti-rabbit IgG HRP conjugate, Promega) were 
detected by enhanced chemiluminescence detection (Thermofisher). This included the 
following antibodies: ACC (3662, Cell Signaling), phospho-ACC (3661, Cell Signaling), 
pan-AMPKα (2532, Cell Signaling), phospho-AMPKα (2535, Cell Signaling), 4EBP1 
(9644, Cell Signaling), phospho-4EBP1 (2855, Cell Signaling), c-myc (9402, Cell 
Signaling), phospho-mTOR (5536, Cell Signaling), Activated Notch (ab8925, Abcam), 
RAPTOR (2280, Cell Signaling), phospho-RAPTOR (2083, Cell Signaling), S6 (2217, Cell 
Signaling), phospho-p70 S6K (9204, Cell Signaling), p70 S6K (2708, Cell Signaling), 
phosphor-TSC2 (5584, Cell Signaling), TSC2 (3612, Cell Signaling). Alternatively, primary 
antibodies were followed by fluorescently labeled anti-mouse or rabbit antibodies (LiCor) 
and imaged using the Odyssey infrared imaging system (LiCor). This included the following 
antibodies: Glut1 (ab652, Abcam), hexokinase 2 (2867, Cell Signaling), hexokinase 1 
(ab104835, Abcam), cytochrome C (556433, BD Biosciences), β-actin (A5441, Sigma), 
phospho-S6 (4858, Cell Signaling). Western blots were quantified using ImageJ software.
Metabolic assays
Glycolysis and glucose uptake assays using 3H-glucose or 3H-2-deoxyglucose have been 
described previously (Gerriets et al., 2015; Macintyre et al., 2014; Wang et al., 2011). 
Pentose phosphate pathway (PPP) flux and glucose oxidation were determined by the rate 
of 14CO2 release from 1-14C-glucose as described (Wang et al., 2011). All values were 
normalized to cell number. OCR and ECAR were measured with an XF24 extracellular flux 
analyzer (Seahorse Bioscience) as described (Caro-Maldonado et al., 2014). Suspension 
cells were attached to culture plates using Cell-Tak (BD Bioscience). OCR and ECAR were 
measured in unbuffered DMEM (Sigma-Aldrich) supplemented with 10mM D-glucose 
(Sigma-Aldrich) and 10mM L-glutamine, as indicated. OCR and ECAR values were 
normalized to cell number. For certain experiments, OCR was measured over time following 
injection of 1 μM oligomycin.
Flow cytometry
The following antibodies were used: anti-human CD4+ VioBlue (Miltenyi), anti-human 
CD8+ APC (Miltenyi), anti-human CD271 (LNGFR)-APC (Miltenyi) and goat anti-rabbit 
PE (eBioscience). Cell death was measured by exclusion of 1 μg/ml propidium iodide. 
Annexin V staining was performed following manufacturer instructions (BD 556547). 
Intracellular staining for GLUT1, HK2 and HK1 and measurement of surface Glut1 by myc 
epitope tag (Millipore 05-724) was performed as previously described (Michalek et al., 
2011). DCFDA, Mitotracker Green and TMRE staining were measured by manufacturer 
protocol (Life Technologies). Data were acquired on a MacsQuant Analyzer (Miltenyi 
Biotec) and analyzed using FlowJo (TreeStar software).
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Complex I Activity Assay
Complex I activity assay was performed following manufacturer instructions (ab109721, 
Abcam). In brief, isolated T-ALL cells were lysed and protein was quantified. 125 μg of 
protein lysate was loaded per well of immunocapture plate. Biological samples were 
analyzed in duplicate technical samples. Lysate was incubated on plate for 3 hr, then plate 
was washed twice and NADH substrate solution was added. OD450 was recorded for each 
well for 30 minutes and Complex I activity was calculated as the increase in OD450 within 
each well.
Statistical Analysis
Statistical analyses were performed with Prism software (GraphPad). Data were analyzed 
using a 2-tailed Student’s t test, and P < 0.05 was considered significant. Survival curve data 
was analyzed using Log Rank (Mantel-Cox) test. Statistically significant results are 
indicated (* p < 0.05) and n.s. indicates select non-significant data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
1. Primary T-ALL cells adopt aerobic glycolysis for cell survival and disease 
progression.
2. T-ALL glucose metabolism is far lower than the capacity of activated T cells.
3. Primary T-ALL cells are ATP depleted and exhibit chronic metabolic stress.
4. AMPK both inhibits anabolic metabolism and is essential for T-ALL cell 
survival.
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Figure 1. Primary T-ALL cell usage of aerobic glycolysis is essential for survival and disease 
progression
A–C. Primary human T-ALL samples and naïve human CD4 T cells were compared for 
expression of (A) Glut1, (B) HK2 and (C) HK1 by intracellular flow cytometry. D. Human 
T-ALL cell lines HPB-ALL, SIL-ALL, and DND41 were compared to naïve human CD4 T 
cells for Glut1, HK2 and HK1 expression by immunoblot. E. Primary human T-ALL and 
naïve human CD4 T cell glucose uptake was measured. F. OCR and ECAR of primary 
murine T-ALL and naïve murine T cells were measured. G. Primary human T-ALL samples 
were treated with vehicle or 10 mM 2DG and the percentage of viable cells that were T-ALL 
cells (CD4+CD8+) or CD4+ T cells was measured by propidium iodide exclusion flow 
cytometry. H–I. Primary T-ALL was generated on a Glut1 inducible deletion background 
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and transplanted into sublethally irradiated recipient mice. Mice were treated with vehicle 
(n=4) or tamoxifen (n=5) for 4 consecutive days starting 4 days after T-ALL transplant and 
survival was monitored (H) or treated with vehicle (n=4) or tamoxifen (n=5) 10 days after 
transplant, sacrificed 2 days after treatment completion to (I) measure T-ALL burden. Data 
are representative of 6 individual human T-ALL samples and 6 independent naïve T cell 
samples (A–C) see also Supplemental Figure 1A–1C, two independent experiments (D–F), 
three independent experiments with individual human T-ALL samples (G) see also 
Supplement Figure 1D–1E or two independent experiments with at least n=4 mice per group 
(H, I). Data are shown as the mean and standard deviation (* p < 0.05).
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Figure 2. Primary T-ALL metabolism is distinct from naïve and activated normal T cells
A–B. Samples of primary murine T-ALL, naïve, and activated T cells were extracted and 
analyzed using high-resolution LC-QE-MS and show a (A) heat map with unsupervised 
hierarchical clustering of the top 250 differentially observed analytes by ANOVA and (B) 
principle component analysis of each sample. C–F. Murine naïve T cells, T cells that were 
activated for 24 or 48 hrs, and purified primary T-ALL cells were analyzed for (C) glucose 
uptake, (D) glycolytic flux, (E) PPP glucose oxidation, (F) mitotracker green and TMRE 
staining. Data are representative of at least 3 biological replicates per group (AB), or at least 
4 independent experiments (C–F); see also Supplemental Figure 4C. Data are shown as the 
mean and standard deviation (* p < 0.05).
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Figure 3. Oncogenic Notch signaling regulates glycolytic and mitochondrial metabolism
A, C–D, F–G, I–L. Lineage negative hematopoietic cells were isolated from the bone 
marrow of wild type (A, D, F–G, I–L) or Glut1myc expressing (C) mice and retrovirally 
transduced with ICN1 or vector control. Cell size by forward scatter (FSC) (A) and surface 
Glut1myc expression (C) were measured by flow cytometry. Total Glut1 and HK2 expression 
were analyzed by immunoblot (D). Virally transduced cells were isolated to measure (F) 
glucose uptake, (G) cytochrome C expression by immunoblot, (I) basal and (J) maximal 
OCR. K–L. Transduced cells were analyzed by flow cytometry for (K) mitotracker green 
staining, (L) TMRE. B, E, H. Human T-ALL cell lines DND41 and HPB-ALL were treated 
with DMSO vehicle or 100 nM Compound E for 96 hrs and (B) cell size was measured by 
FSC. Cell lysates were also analyzed by immunoblot for (E) HK2 and (H) cytochrome C 
expression. Data are representative of at least three independent experiments. Data are 
shown as the mean and standard deviation (* p < 0.05).
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Figure 4. Oncogenic Notch signaling drives metabolic stress and AMPK pathway activation in T-
ALL
A. Primary murine T-ALL, naïve and activated T cells were analyzed by immunoblot. B. 
Two independent samples of primary human T-ALL and naïve CD4+ T cells were analyzed 
by immunoblot. C. Lineage negative hematopoietic cells were isolated from the bone 
marrow of wild type mice and retrovirally transduced with ICN1 or vector control and 
analyzed by immunoblot. D. Human T-ALL cell lines DND41 and HPB-ALL were treated 
with vehicle or 100 nM Compound E for 96 hrs and analyzed by immunoblot. E–G. Murine 
naïve T cells and purified primary T-ALL cells were and samples were extracted and 
analyzed using high-resolution LC-QE-MS for metabolomics analysis. Data are 
representative of at least three independent experiments (A, C–D), two independent human 
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T-ALL samples (B) or at least four independent biological replicates (E–G). Data are shown 
as the mean and standard deviation (* p < 0.05).
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Figure 5. AMPK signaling negatively regulates mTORC1 and inhibits aerobic glycolysis in T-
ALL
Primary T-ALL was generated on an AMPKα1 inducible deletion background and 
transplanted into sublethally irradiated recipient mice. Mice were treated with vehicle or 
tamoxifen for 4 days starting 10 days after transplant and sacrificed 2 days after treatment 
completion. A–C. Purified T-ALL cells from vehicle and tamoxifen treated groups were 
isolated and (A–B) analyzed by immunoblot (C) ECAR was measured. D–G. Isolated T-
ALL cells from four separate mice in vehicle and tamoxifen treated groups were examined 
by rtPCR for select PPP gene expression (D) or were (E–G) extracted and analyzed using 
high-resolution LC-QE-MS. The normalized abundance of select metabolites is shown. Data 
are representative of two independent experiments with three independent T-ALL samples 
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per group (A–C) or an experiment with four independent T-ALL samples per group (D–G). 
Data are shown as the mean and standard deviation. Western blot quantifications are 
normalized to total protein level where applicable or to actin (* p < 0.05).
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Figure 6. AMPK promotes mitochondrial oxidative metabolism in T-ALL through the regulation 
of Complex I
Primary T-ALL was generated on an AMPKα1 inducible deletion background and 
transplanted into sublethally irradiated recipient mice. A–D. Mice were treated with vehicle 
or tamoxifen for 4 days starting 10 days after transplant and sacrificed 2 days after treatment 
completion. Purified T-ALL cells from vehicle and tamoxifen treated groups were isolated 
and (A) OCR, (B) OCR/ECAR ratio and (C) ATP coupled OCR, defined as oligomycin 
sensitive OCR, were measured or (D) cells were analyzed using high-resolution LC-QE-MS. 
The normalized abundance of select metabolites is shown. E–G. T-ALL cells were isolated 
from vehicle and tamoxifen treated mice for (E) Flow cytometry analysis of DCFDA and (F) 
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rtPCR measurement of select mitochondrial energy pathway gene expression (G) analysis of 
Complex I enzyme activity. Unsupervised hierarchical clustering of gene expression is 
shown for panels F. Data represent an experiment with four independent T-ALL samples per 
group (A–D, F–G), or two independent experiments with n = 8 per group (E). Data are 
shown as the mean and standard deviation (* p < 0.05).
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Figure 7. AMPK and mitochondrial Complex I activity are necessary to maintain T-ALL cell 
viability and disease progression
A–E. Primary T-ALL was generated on an AMPKα1 inducible deletion background and 
transplanted into sublethally irradiated recipient mice. (A–D). Mice were treated with 
vehicle or tamoxifen for 4 days starting 10 days after transplant and sacrificed 2 days after 
treatment completion. T-ALL cell burden and percentage present in the (A) spleen, (B) 
inguinal lymph nodes, and (C) bone marrow were determined by flow cytometry. D. 
Annexin V and propidium iodide staining was measured by flow cytometry. (E) Mice were 
treated with vehicle or tamoxifen for 4 days beginning 4 days after transplant and given 
daily 4-hydroxytamoxifen (5 mg/kg body weight) for 5 days beginning 10 days after 
transplant to maintain gene deletion and overall survival was measured. F–I. Primary murine 
T-ALL was generated on a wild type background. T-ALL was isolated and, (F) along with 
Kishton et al. Page 28
Cell Metab. Author manuscript; available in PMC 2017 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
naïve T cells and T cells that were activated in vitro for 48 hrs, were treated with 100 nM 
rotenone or DMSO vehicle or (G) 100 μM phenformin or PBS vehicle and cell survival was 
measured over time by propidium iodide exclusion flow cytometry. Viability normalized to 
vehicle treatment is shown. Isolated T-ALL was treated for 45 minutes with 100 μM 
phenformin or PBS vehicle and (H) OCR and (I) ECAR were measured. J–L. Primary 
murine T-ALL was transplanted into sublethally irradiated recipient mice. Mice were dosed 
daily with vehicle (PBS) or phenformin (100 mg/kg body weight) for 10 consecutive days 
starting two days after T-ALL transplant. Mice were rested for 2 days, sacrificed and (J) 
DCFDA staining, (K) spleen cellularity and (L) T-ALL cell burden in the spleen were 
analyzed for each group. Data are representative of three independent experiments with at 
least five mice per group (A), an experiment with seven mice per group (B–D), an 
experiment with ten mice per group (E), three independent experiments (F–I) or two 
independent experiments with at least five mice per group (J–L). Data are shown as the 
mean and standard deviation (* p < 0.05).
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